Open Interest and Volume Dynamics
On 28 Sep 2026, Glenmark Pharmaceuticals recorded an open interest (OI) of 44,011 contracts, up from 37,985 the previous day, marking an increase of 6,026 contracts or 15.86%. This rise in OI is accompanied by a futures volume of 26,346 contracts, reflecting robust trading activity in the derivatives market. The futures value stood at approximately ₹1,32,231 lakhs, while the options segment exhibited a substantial notional value of ₹10,272.3 crores, culminating in a combined derivatives market value of ₹1,33,124 lakhs for Glenmark.
The underlying stock price closed at ₹2,327, having opened with a gap down of 2.34% and touched an intraday low of ₹2,324.1. Notably, the stock has been on a three-day losing streak, declining 6.05% over this period, underperforming its sector by 1.46% and the Sensex by 0.76% on the day.
Price Action and Moving Averages
Despite the recent downward momentum, Glenmark’s price remains above its 100-day and 200-day moving averages, suggesting that the longer-term trend retains some underlying strength. However, the stock trades below its 5-day, 20-day, and 50-day moving averages, indicating short- to medium-term weakness. The weighted average price for the day was closer to the intraday low, signalling that most volume was transacted near the lower price levels, which could imply selling pressure or cautious positioning by traders.
Investor Participation and Liquidity
Investor participation has notably increased, with delivery volumes rising to 4.9 lakh shares on 25 Sep, a 60.53% jump compared to the five-day average delivery volume. This heightened participation suggests that investors are actively adjusting their holdings amid the recent price volatility. The stock’s liquidity remains adequate, with a trade size capacity of approximately ₹2.67 crores based on 2% of the five-day average traded value, facilitating smooth execution of sizeable trades without significant market impact.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Interpreting the Open Interest Surge
The 15.9% increase in open interest is a significant development, especially in the context of a falling stock price. Typically, rising open interest alongside a declining price can indicate that new short positions are being established, as traders anticipate further downside. Alternatively, it may reflect fresh long positions being opened as investors seek to capitalise on perceived undervaluation or upcoming catalysts.
Given the stock’s recent three-day decline and the volume concentration near the day’s low, the market appears to be positioning cautiously. The increase in OI suggests that participants are actively engaging in the derivatives market to hedge or speculate on Glenmark’s near-term direction.
Directional Bets and Market Positioning
Market participants seem to be taking mixed directional bets. The futures and options notional values indicate substantial interest in both segments, with options activity particularly elevated. This could imply that traders are employing strategies such as protective puts or call spreads to manage risk amid uncertainty.
Moreover, the stock’s Mojo Score of 72.0 and an upgraded Mojo Grade from Hold to Buy as of 21 Sep 2026 reflect improving fundamentals and positive analyst sentiment. This upgrade may be encouraging some investors to initiate fresh long positions, anticipating a rebound after the recent correction.
Sector and Market Context
Within the Pharmaceuticals & Biotechnology sector, Glenmark’s underperformance relative to the sector’s 0.77% decline and the broader Sensex’s 1.59% drop highlights stock-specific pressures. However, the mid-cap company’s sizeable market capitalisation of ₹65,591.84 crores and improving mojo metrics suggest it remains a key player with potential for recovery.
Curious about Glenmark Pharmaceuticals Ltd. from Pharmaceuticals & Biotechnology? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Outlook and Investor Considerations
Investors should closely monitor Glenmark’s derivatives activity as a barometer of market sentiment. The rising open interest amid a price decline suggests that volatility and positioning shifts are underway. Traders with a bullish outlook may view the recent correction and upgraded mojo grade as an opportunity to accumulate, while cautious investors might prefer to wait for confirmation of a trend reversal.
Given the stock’s liquidity and active participation, it remains accessible for both institutional and retail investors seeking exposure to the Pharmaceuticals & Biotechnology sector. However, the narrow intraday trading range and volume concentration near lows indicate that momentum is currently subdued, warranting careful risk management.
Conclusion
Glenmark Pharmaceuticals Ltd.’s surge in open interest by nearly 16% amidst a three-day price decline highlights a complex market environment with active positioning and mixed directional bets. The stock’s upgraded mojo grade and solid mid-cap status provide a foundation for potential recovery, but short-term technicals suggest caution. Investors should weigh the evolving derivatives landscape alongside fundamental and sectoral factors to make informed decisions in this dynamic market setting.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
